"A Pilot Study to Assess the Safety, Tolerability and Efficacy of Virtual Reality for the Treatment of Gastroparesis"
Trial Snapshot
- Phase
- Not Applicable
- Status
- Suspended
- Sponsor
- Mayo Clinic
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Patient-reported adverse events
Study Overview
Brief Summary
The purpose of this study is to determine if virtual reality therapy is safe and tolerable in treating gastroparesis.
Detailed Description
After informed consent patients will be randomized to a 4 week treatment program comparing active VR treatment to sham VR treatment. Symptoms will be measured at baseline and at 2 and 4 weeks using validated questionnaires. A short questionnaire will be answered daily to evaluate changes in nausea.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
double blind, randomized.
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult patients, men and women ages 18-
- •Documented gastroparesis (idiopathic or diabetic).
- •Patients who have had an upper endoscopy within the past 3 years not showing evidence of an organic disorder that could cause symptoms and a 4-hour scintigraphic gastric emptying scan showing evidence of delayed gastric emptying.
- •Patients will be identified as direct referrals to the general GI clinic or the motility clinic, and will undergo screening history and physical examination by the PI or co-investigator.
Exclusion Criteria
- •Patients whose symptoms are thought to represent an organic disorder (e.g., peptic ulcer disease, hepatitis, pancreatitis, inflammatory bowel disease, a known malignancy, radiation-induced injury, an active infection, vasculitis, celiac disease).
- •If the patients have known uncontrolled diabetes (HgbA1c > 11), GERD, esophagitis, eosinophilic esophagitis, H. pylori, cannabinoid hyperemesis syndrome, celiac artery compression syndrome, or SMA syndrome.
- •Patients with prior surgery to the esophagus, stomach or duodenum.
- •Patients taking opioids will also be excluded.
- •Alcohol and tobacco use will be assessed, as will the presence of psychiatric conditions, such as anxiety, depression, post-traumatic stress disorder, bipolar disorders, and eating disorders, such as anorexia nervosa and bulimia. However, no patient will be excluded based on reported substance use or presence of a psychiatric comorbidity, unless their psychological status represents potential harm to themselves, others, or represents an impediment to treatment.
- •Any patient identified as having a significant problem with alcohol or anxiety or depression will be referred back to their primary care provider for further evaluation and treatment.
- •Patients with motion sickness, vertigo, or a seizure disorder will be excluded to prevent the theoretical risk of inducing or exacerbating symptoms related to the aforementioned conditions with VR.
Arms & Interventions
Active VR Group
Subjects will be provided an Oculus Go VR headset pre-loaded with a "menu" of virtual reality programs which have been designed specifically to treat both acute and chronic pain. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes.
Intervention: Oculus Go VR headset (Device)
Sham VR Group
Subjects will be provided an Oculus Go VR headset pre-loaded two-dimensional nature video. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes.
Intervention: Sham Oculus Go VR headset (Device)
Outcomes
Primary Outcomes
Patient-reported adverse events
Time Frame: 4 weeks
Number of patient-reported adverse events assessed using standardized daily patient-reported adverse event questionnaires
Secondary Outcomes
- Changes in global gastroparesis symptom scores(Baseline, 4 weeks)
- Changes in gastrointestinal disorder symptoms(Baseline, 4 weeks)
- Changes in abdominal pain(Baseline, 4 weeks)
- Changes in individual scores for nausea(Baseline, 4 weeks)
- Change in work productivity(Baseline, 4 weeks)
- Change in Quality of life(Baseline, 4 weeks)
- Changes in bloating(Baseline, 4 weeks)
Investigators
Brian Lacy
Principal Investigator
Mayo Clinic